Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 479 · 1 trial · 3 indications
Objective response rate is the percentage of patients achieving partial response (PR) or complete response (CR) per RECIST 1.0 criteria. For target lesions, CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. CR or PR status must be confirmed by repeat assessments performed no fewer than 4 weeks or more than 6 weeks after the response criteria are first met. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.
| Arm | Type | Description |
|---|---|---|
| AMG 479 | EXPERIMENTAL | Patients receive AMG 479 at a dose of 18 mg/kg administered IV on day 1 (± 3 days) of every 3-week cycle. Treatment should continue until disease progression, unacceptable toxicity or withdrawal of consent. |
| Name | Type | Description |
|---|---|---|
| AMG 479 | DRUG | - |
Inclusion Criteria: * Locally unresectable or metastatic carcinoid or pancreatic neuroendocrine tumors. To be classified as having a pancreatic neuroendocrine tumor, patients must have clinical evidence of currently having or having had a primary pancreatic neuroendocrine lesion. * Measurable disea...
AMG 479 is an investigational small molecule being studied for the treatment of neuroendocrine tumors, including carcinoid tumors and pancreatic neuroendocrine tumors. It is being developed by Amgen Inc. and is currently in Phase 2 clinical development.
AMG 479 is a small molecule, but its specific molecular target has not been disclosed. It is being investigated for its potential role in treating neuroendocrine tumors, though the exact mechanism of action is not publicly detailed.
AMG 479 is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The drug is currently in Phase 2 clinical development for neuroendocrine tumors.
AMG 479 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, with no active trials currently ongoing.
AMG 479 has been studied in one completed Phase 2 clinical trial, identified as NCT01024387. This trial, titled 'AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors,' enrolled 60 participants in the United States and was not randomized or blinded.
AMG 479 is not known by any alternative names. It is a distinct investigational small molecule being developed by Amgen Inc. for the treatment of neuroendocrine tumors.